Video

Q&A With Pers Sorensen From Copenhagen University: ECTRIMS Grows As Treatment Options For Multiple Sclerosis Expands

Author(s):

In 1992 the European Committee For Treatment And Research in Multiple Sclerosis met in Barcelona with 200 people in attendance. Twenty three years later the same conference was held in the same city with more than 9000 people in attendance and more than 1000 abstracts submitted.

In 1992 the European Committee For Treatment And Research in Multiple Sclerosis (ECTRIMS) met in Barcelona with 200 people in attendance. Twenty three years later the same conference was held in the same city with more than 9000 people in attendance and more than 1000 abstracts submitted.

Pers Sorenson, MD, DMSc, from Copenhagen University Hospital, who also serves as Secretary General for ECTRIMS discussed how the conference has grown during the most recent meeting in the Spanish city.

Treatment for the relapsing remitting form of multiple sclerosis has improved by leaps and bounds over the past few years and there are signs of progress for the primary progressive form as well. Even while improvements have been made there is still much more work to be done in the field.

Related Videos
Kimberly A. Davidow, MD: Elucidating Risk of Autoimmune Disease in Childhood Cancer Survivors
Yehuda Handelsman, MD: Insulin Resistance in Cardiometabolic Disease and DCRM 2.0 | Image Credit: TMIOA
Nathan D. Wong, MD, PhD: Growing Role of Lp(a) in Cardiovascular Risk Assessment | Image Credit: UC Irvine
Laurence Sperling, MD: Expanding Cardiologists' Role in Obesity Management  | Image Credit: Emory University
Laurence Sperling, MD: Multidisciplinary Strategies to Combat Obesity Epidemic | Image Credit: Emory University
Schafer Boeder, MD: Role of SGLT2 Inhibitors and GLP-1s in Type 1 Diabetes | Image Credit: UC San Diego
Matthew J. Budoff, MD: Examining the Interplay of Coronary Calcium and Osteoporosis | Image Credit: Lundquist Institute
Alice Cheng, MD: Exploring the Link Between Diabetes and Dementia | Image Credit: LinkedIn
© 2024 MJH Life Sciences

All rights reserved.